Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003414 · ClinicalTrials.gov registry record · Phase 3
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
A Phase 3 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT00003414 is a Phase 3 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 50 participants.
The verdict
NCT00003414, a Phase 3 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an immune response that will kill cancer cells. Interleukin-2 and interferon gamma may enhance the effectiveness of graft-versus-host disease to kill cancer cells. PURPOSE: Randomized phase III trial to determine the effectiveness of graft-versus-host disease in treating patients who have recurrent or refractory lymphoma or Hodgkin's disease .
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL aldesleukin
- DRUG busulfan
- DRUG cyclosporine
- BIOLOGICAL recombinant interferon gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1997-10 |
| Est. Completion | 2004-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003414
The ClinicalTrials.gov registry entry for NCT00003414 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003414 about?
NCT00003414 is a clinical study titled "Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease". RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an immune response that will kill cancer cells. Interleukin-2 and interferon gamma may enhance the effectiveness of graft-versus-host disease to kill cancer cells. PURPOSE: Randomized phase III trial to determine t...
What is the current status of trial NCT00003414?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 1997-10. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00003414?
The interventions under investigation include: cyclophosphamide (DRUG), aldesleukin (BIOLOGICAL), busulfan (DRUG), cyclosporine (DRUG), recombinant interferon gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003414?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.